Andrew Chipouras is a patent attorney practicing in all areas of patent law with a focus on preparing and prosecuting patent applications. In particular, he has experience working with clients to protect inventions inventions and strategically manage patent portfolios in technologies from chemistry and the life sciences to materials science and mechanical/electromechanical technologies.

Andrew conducts due diligence on patent portfolios for licensing, acquisition, and investment transactions, prepares freedom-to-operate and invalidity opinions, and supports patent litigation and inter partes review proceedings.


Practice Areas


Representative Matters

  • Represented petitioner in inter partes review of medical device patents, resulting in cancellation of all challenged claims and dismissal of parallel district court proceeding.
  • Represented innovator pharmaceutical company in Hatch-Waxman patent litigation to protect client’s flagship drug.  Obtained consent judgments with injunctions against all defendants.

Helped obtain U.S. patents for clients, including:

  • U.S. Patent No. 11,786,461 (Naloxone formulations for sublingual and/or buccal administration)
  • U.S. Patent No. 11,718,622 (Heterocyclic adenosine receptor antagonists)
  • U.S. Patent No. 11,633,394 (Substituted alkynylene compounds as anticancer agents)
  • U.S. Patent No. 11,597,699 (MEK inhibitors and methods of their use)
  • U.S. Patent No. 11,512,081 (Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell)
  • U.S. Design Patent No. D964,199 (Safety Beacon)
  • U.S. Patent No. 11,427,605 (Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine)
  • U.S. Patent No. 11,198,731 (Combinations of cabozantinib and atezolizumab to treat cancer)
  • U.S. Patent No. 11,186,576 (Pyrazolo[1,5-a][1,3,5]triazine and pyrazole[1,5-a]pyrimidine derivatives as CDK inhibitors
  • U.S. Patent No. 11,174,232 (Substituted heterocyclic derivatives as CDK inhibitors)
  • U.S. Patent No. 11,123,337 (4-methylsulfonyl-substituted piperidine urea compounds)
  • U.S. Patent No. 11,077,086 (Solid dosage form composition for buccal or sublingual administration of cannabinoids)
  • U.S. Patent No. 10,815,150 (Method for producing concrete elements)
  • U.S. Patent No. 10,793,541 (Process for making compound for use in the treatment of cancer)
  • U.S. Patent No. 10,590,102 (Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone)
  • U.S. Patent No. 10,371,100 (Carburetor and methods therefor)
  • U.S. Patent No. 9,902,903 (Electroluminescent compositions)
  • U.S. Patent No. 9,799,886 (Cathode with silver material and silicate dopant and method of producing)
  • U.S. Patent No. 9,708,371 (Treatments for gastrointestinal disorders)
  • U.S. Patent No. 9,680,193 (Electrically rechargeable, metal anode cell and battery systems and methods)
  • U.S. Patent No. 9,670,479 (Sample preparation device and methods of use)
  • U.S. Patent No. 9,634,359 (Electrolyte for zinc-based rechargeable batteries, method for producing the same and batteries including said electrolyte)
  • U.S. Patent No. 9,192,786 (Real-time, on-line and offline treatment dose tracking and feedback process for volumetric image guided adaptive radiotherapy)
  • U.S. Patent No. 8,948,848 (Angiography catheter)
  • U.S. Patent No. 8,802,304 (Bifunctional (rechargeable) air electrodes comprising a corrosion-resistant outer layer and conductive inner layer)
  • U.S. Patent No. 8,670,523 (Intensity modulated arc therapy with continuous couch rotation/shift and simultaneous cone beam imaging)

Prior Experience

  • Dow Corning, IP Intern, 2014
  • Honigman, Patent Agent, 2012-2013
  • F Cubed LLC, Engineering Intern, 2010-2011




Court Admissions



Managing Intellectual Property IP STARS, Rising Star, 2021

The Best Lawyers in America, 2023 - 2024

  • Recognized in practice areas of:
    • Intellectual Property Law, Ones to Watch
    • Litigation - Intellectual Property, Ones to Watch
    • Patent Law, Ones to Watch

Professional & Community Involvement

American Intellectual Property Law Association (AIPLA)

  • Chemical Practice Committee
  • Professional Programs Committee

Big Brothers Big Sisters

Notre Dame Club of Kalamazoo

News & Insights

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.